El Benna Houda, Bousrih Chayma, Rachdi Haifa*, Mejri Nesrine, Daoud Nouha, Labidi
Soumaya and Boussen Hamouda
Department of Medical Oncology, Tunis El Manar University, TunisiaFulltext PDF
Tumor Lysis Syndrome (TLS) is a major oncological emergency involving metabolic perturbations. TLS is usually observed after aggressive treatment or spontaneously in rapidly growing hematological malignancies and exceptionally in solid cancers. Dihydropyrimidine Dehydrogenase (DPD) is the first enzyme acting in the catabolism of 5-fluorouracil (5FU). Patients with a partial deficiency of this enzyme are at risk for developing a severe 5FU-associated toxicity. We report here a rare case of TLS secondary to DPD deficit in a patient treated with concurrent chemoradiation for a locally advanced rectal cancer.
Houda EB, Chayma B, Haifa R, Nesrine M, Nouha D, Soumaya L, et al. Tumor Lysis Syndrome under Concurrent Chemoradiation for Rectal Cancer in a Patient with Dihydropyrimidin Deficiency. Ann Clin Case Rep. 2019; 4: 1689 .